EMEA-000310-PIP03-10-M05
Key facts
| Invented name |
Ocrevus
|
| Active substance |
ocrelizumab
|
| Therapeutic area |
Neurology
|
| Decision number |
P/0305/2021
|
| PIP number |
EMEA-000310-PIP03-10-M05
|
| Pharmaceutical form(s) |
Concentrate for solution for infusion
|
| Condition(s) / indication(s) |
Treatment of multiple sclerosis
|
| Route(s) of administration |
Intravenous use
|
| Contact for public enquiries |
Roche Registration GmbH
Tel. +41 616879411 |
| Decision type |
PM: decision on the application for modification of an agreed PIP
|